Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
163 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hyperlipidemia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hyperlipidemia - Pipeline Review, H2 2014', provides an overview of the Hyperlipidemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Hyperlipidemia Overview 8 Therapeutics Development 9 Pipeline Products for Hyperlipidemia - Overview 9 Pipeline Products for Hyperlipidemia - Comparative Analysis 10 Hyperlipidemia - Therapeutics under Development by Companies 11 Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 14 Hyperlipidemia - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Hyperlipidemia - Products under Development by Companies 17 Hyperlipidemia - Products under Investigation by Universities/Institutes 20 Hyperlipidemia - Companies Involved in Therapeutics Development 21 ACROVIS biostructures GmbH 21 Advinus Therapeutics Ltd. 22 Angion Biomedica Corp. 23 BiOrion Technologies B.V. 24 Celgene Corporation 25 Digna Biotech, S.L. 26 FibroGen, Inc. 27 Galectin Therapeutics, Inc. 28 Genfit SA 29 GenKyoTex S.A. 30 Gilead Sciences, Inc. 31 GNI Group Ltd. 32 La Jolla Pharmaceutical Company 33 LG Life Sciences, Ltd. 34 Nitto Denko Corporation 35 Pfizer Inc. 36 Pharmaxis Limited 37 Promedior, Inc. 38 Promethera Biosciences S.A. 39 ProMetic Life Sciences Inc. 40 RXi Pharmaceuticals Corporation 41 Silence Therapeutics plc 42 TCM Biotech International Corp 43 Virobay Inc. 44 Hyperlipidemia - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 AbyD-3263 - Drug Profile 54 ANG-3281 - Drug Profile 55 ANG-3298 - Drug Profile 56 ANG-4011 - Drug Profile 57 BOT-162 - Drug Profile 58 BOT-191 - Drug Profile 59 CC-539 - Drug Profile 60 CC-90001 - Drug Profile 61 CIGB-500 - Drug Profile 62 CT-140 - Drug Profile 63 DB-036 - Drug Profile 64 disitertide - Drug Profile 65 Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis - Drug Profile 67 F-351 - Drug Profile 68 FG-3019 - Drug Profile 70 GCS-100 - Drug Profile 72 GFT-505 - Drug Profile 74 GKT-137831 - Drug Profile 77 GM-CT-01 - Drug Profile 78 GM-CT-02 - Drug Profile 81 GR-MD-01 - Drug Profile 82 GR-MD-02 - Drug Profile 84 HepaStem - Drug Profile 86 KBP-7018 - Drug Profile 88 KW-0 - Drug Profile 89 LC-280126 - Drug Profile 90 LJPC-201 - Drug Profile 92 melittin - Drug Profile 93 ND-L02s0201 - Drug Profile 94 NPLC-0393 - Drug Profile 96 P-17 - Drug Profile 97 PBI-4050 - Drug Profile 99 PRI-724 - Drug Profile 100 PRM-151 - Drug Profile 102 PXS-4728A - Drug Profile 104 PXS-5033-A - Drug Profile 105 RNAi Oligonucleotide for Hepatocellular Carcinoma, Ischemia Reperfusion Injury and Fulminant Fibrosis - Drug Profile 106 RXI-209 - Drug Profile 107 simtuzumab - Drug Profile 108 Small Molecule for Liver Fibrosis - Drug Profile 110 Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 111 Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 112 Small Molecules for Liver Diseases - Drug Profile 113 Small Molecules to Inhibit EGFR for Gastrointestinal Disorders - Drug Profile 114 Stem Cell Therapy for Liver Fibrosis and Liver Diseases - Drug Profile 115 Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology - Drug Profile 116 TCM-808FB - Drug Profile 117 TGFTX-4 Program - Drug Profile 118 VBY-376 - Drug Profile 119 VBY-825 - Drug Profile 120 Hyperlipidemia - Recent Pipeline Updates 121 Hyperlipidemia - Dormant Projects 150 Hyperlipidemia - Discontinued Products 151 Hyperlipidemia - Product Development Milestones 152 Featured News & Press Releases 152 Appendix 159 Methodology 159 Coverage 159 Secondary Research 159 Primary Research 159 Expert Panel Validation 159 Contact Us 160 Disclaimer 160
List of Tables Number of Products under Development for Hyperlipidemia, H2 2014 12 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Products under Development by Companies, H2 2014 20 Products under Development by Companies, H2 2014 (Contd..1) 21 Products under Development by Companies, H2 2014 (Contd..2) 22 Products under Investigation by Universities/Institutes, H2 2014 23 Hyperlipidemia - Pipeline by ACROVIS biostructures GmbH, H2 2014 24 Hyperlipidemia - Pipeline by Advinus Therapeutics Ltd., H2 2014 25 Hyperlipidemia - Pipeline by Angion Biomedica Corp., H2 2014 26 Hyperlipidemia - Pipeline by BiOrion Technologies B.V., H2 2014 27 Hyperlipidemia - Pipeline by Celgene Corporation, H2 2014 28 Hyperlipidemia - Pipeline by Digna Biotech, S.L., H2 2014 29 Hyperlipidemia - Pipeline by FibroGen, Inc., H2 2014 30 Hyperlipidemia - Pipeline by Galectin Therapeutics, Inc., H2 2014 31 Hyperlipidemia - Pipeline by Genfit SA, H2 2014 32 Hyperlipidemia - Pipeline by GenKyoTex S.A., H2 2014 33 Hyperlipidemia - Pipeline by Gilead Sciences, Inc., H2 2014 34 Hyperlipidemia - Pipeline by GNI Group Ltd., H2 2014 35 Hyperlipidemia - Pipeline by La Jolla Pharmaceutical Company, H2 2014 36 Hyperlipidemia - Pipeline by LG Life Sciences, Ltd., H2 2014 37 Hyperlipidemia - Pipeline by Nitto Denko Corporation, H2 2014 38 Hyperlipidemia - Pipeline by Pfizer Inc., H2 2014 39 Hyperlipidemia - Pipeline by Pharmaxis Limited, H2 2014 40 Hyperlipidemia - Pipeline by Promedior, Inc., H2 2014 41 Hyperlipidemia - Pipeline by Promethera Biosciences S.A., H2 2014 42 Hyperlipidemia - Pipeline by ProMetic Life Sciences Inc., H2 2014 43 Hyperlipidemia - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 44 Hyperlipidemia - Pipeline by Silence Therapeutics plc, H2 2014 45 Hyperlipidemia - Pipeline by TCM Biotech International Corp, H2 2014 46 Hyperlipidemia - Pipeline by Virobay Inc., H2 2014 47 Assessment by Monotherapy Products, H2 2014 48 Number of Products by Stage and Target, H2 2014 50 Number of Products by Stage and Mechanism of Action, H2 2014 52 Number of Products by Stage and Route of Administration, H2 2014 54 Number of Products by Stage and Molecule Type, H2 2014 56 Hyperlipidemia Therapeutics - Recent Pipeline Updates, H2 2014 124 Hyperlipidemia - Dormant Projects, H2 2014 153 Hyperlipidemia - Discontinued Products, H2 2014 154
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
